A genetic study following the role of genetic pathways associated with CDKN2A in tumor progression and prognosis delineated the significant implication of p16 loss in the progression of melanoma, as opposed to the intermittent role of p14 alterations.[17] In our study, this affirmation was supported by the association between higher Breslow indexes in the case of p16 immunohistochemical absent expression (P-value = .0001) than those encountered in melanoma slides with p14 loss (P-value = .001). Here, CDKN2A is linked to melanoma.